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Category  Severe  Attenuated allc  Attenuated poor  Attenuated intermediate  Attenuated mild 
Age of onset           
N  56  42  6  12  15 
1st week  49  20  5  5  7 
> 1 week  7  22  1  7  8 (> 4 months in 7) 
Oldest  2 months  3 year  2 months  4 months  3 year 
Brain Malformation           
N (with brain imaging data)  45  40  6  12  15 
Corpus callosum agenesis   9  0  0  0  0 
Corpus callosum hypoplasia  18  3  1  0  0 
Cerebellar cyst/hydrocephalus  4  0  0  0  0 
Brain atrophy  1  0  0  0  0 
No malformations  13  34  5  12  15 





Glycine levels           
Plasma glycine levels µM           
      Median, N  1055 , N=48  827 , N=37a  844 , N=6  760 , N=12  829 , N=15 
      Range  324‐2048  342‐1590  552‐1433  509‐1120  470‐1196 
CSF glycine levels µM           
      Median, N  213 , N=46  89 , N=31b  138 , N=6  89 , N=11  63 , N=11 
      Range  40‐510  41‐230  103‐172  51‐230  41.4‐154 
CSF:plasma glycine ratio           
      Median, N  0.22 , N=45  0.12 , N=29b  0.17 , N=5  0.14 , N=11  0.08 , N=9 











  N  Pearson R2  p value  Spearman Rho  p value 
Attenuated NKH only           
Age onset  33  0.247  0.003  0.384  0.03 
Antiepileptic drugs  33  ‐0.260  0.002  ‐0.582  <0.001 
CSF glycine  28  ‐0.315  0.002  ‐0.664  <0.001 
CSF:plasma glycine  24  ‐0.328  0.003  ‐0.544  0.005 
Glycine index  12  ‐0.424  0.02  ‐0.765  0.004 
Attenuated and Severe           
Age onset  88  0.311  <0.001  0.433  <0.001 
Antiepileptic drugs  56  ‐0.599  <0.001  ‐0.827  <0.001 
CSF glycine  74  ‐0.296  <0.001  ‐0.681  <0.001 
CSF:plasma glycine  70  ‐0.289  <0.001  ‐0.622  <0.001 
Plasma glycine  81  ‐0.081  0.01  ‐0.266  0.02 
Glycine index  20  0.645  <0.001  ‐0.904  <0.001 
Mutation score  81  ‐0.479  <0.001  0.674  <0.001 
 
Legend: Correlation between DQ and each of the predictive factors.  




















Parameter  Outcome  Sensitivity  Specificity 
Onset > 4 months  Attenuated mild  47%  100% 
Onset 1st week  Severe  87%  70% 
CSF glycine > 230 µM  Severe  43%  100% 
CSF:plasma glycine ratio ≤ 0.08  Attenuated  28%  100% 
Brain malformation severe  Severe  29%  100% 
Brain malformation all (incl. HCC)  Severe  71%  92% 
No epilepsy (no AED)  Attenuated   70%  100% 
Glycine index > 3a  Severe  87%  100% 
2 non‐missense mutations  Severe  36%  95% 
Mutation scoreb ‐2  Severe  59%  97% 


























Figure 1: Differences in antiepileptic drugs, glycine levels, and glycine index by disease category  
Legend: A. The differences between severe NKH, poor attenuated NKH, intermediate attenuated NKH, and 
mild attenuated NKH are shown for the number of antiepileptic drugs (A), the CSF glycine levels (B), the 
CSF:plasma glycine ratios (C), and the glycine index (D).  
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Figure 2: Relation between CSF glycine levels and DQ  
Legend:  There is a direct linear correlation between CSF glycine levels and DQ. The cutoff at 230 µM is 
shown.  
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Figure 3: Mutations in GLDC  
Legend: Missense mutations are shown above the diagram of the exonic structure of the GLDC gene (A). 
Missense mutations with residual activity are shown in green, and missense mutations without residual 
activity are shown in red, mutations not expressed in yellow. Frameshift mutations (grey) and splice site 
mutations (orange) are shown below the exonic structure. The length of observed exonic deletions is shown 
in red and duplications in blue. The frequency of occurrence is provided for recurring mutations.  
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Figure 4: Mutations in AMT  
Legend: Missense mutations (yellow) are shown above the diagram of the exonic structure of the AMT gene. 
Frameshift mutations (grey) and splice site mutations (orange) are shown below the exonic structure.  
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Figure 5: Number of residual activity conferring mutations and disease severity  
Legend: A. The frequency of developmental outcome in categories of severe, attenuated poor, attenuated 
intermediate, attenuated mild, or attenuated not otherwise specified (NOS, without known DQ) is shown in 
relation to the number of alleles with a mutation conferring no residual activity (severe mutation) or alleles 
with a mutation conferring residual activity (mild mutation). B. The frequency of patients requiring a number 
of antiepileptic medications in relation to the number of severe or mild alleles.  
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Figure 6: Mutation score by disease category  
Legend: The mutation score is compared between neonatal deceased, severe NKH, poor attenuated NKH, 
intermediate attenuated NKH, mild attenuated NKH, and attenuated NKH NOS. The mutation score is 
significantly higher in attenuated NKH than in severe or neonatal decreased NKH.  
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Figure 7: Molecular modeling of mutated amino acids on the structure of the P-protein  
Homology structure of the human P-protein dimer modeled from Synechocystis sp. is shown with the amino 
acids of the expressed missense mutations highlighted. Amino acids involved in missense mutations without 
residual activity on expression study are shown in red, with < 1% residual activity in blue, with 1-10% 
residual activity in yellow, and > 10% residual activity in green. The active site lysine 754 is shown in pink. 
Amino acids which when mutated result in a stable protein (identified in the lower part) tend to cluster 
around the active site fold (red circle) whereas amino acids which when mutated result in unstable protein 
(identified in the upper part) tend to be located away from the active site fold.    
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Figure 8: Western blot analysis of expressed mutations in GLDC  
Legend: The missense mutations present in two patients were expressed in COS cells, and the level of P-
protein identified by Western blot. The amount of β-actin protein is shown as a loading control.  
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C 27 USA ND M 1 we 0.2 0 1393 294 0.21 P Del exon 1-2 X c.2498C>T; p.A833V 7 -2 -2
C 69 BEL ND M 1 we 0.2 ACC 940 254 0.27 0 P c.2422A>C ;  p.S808R 3 c.538C>T ; p.Q180X X -2 -2
C 66 NET ND F 1 we 0.2 ACC 1186 270 0.23 P c.1009C>T ; p.R337X X c.1009C>T ;  p.R337X X -2 -2
C 227 USA ND M 1 we 0.2 ACC 1188 190 0.16 P Del exon 1-17 X Del exon 5-8 X -2 -2
C 168 USA ND M 1 we 0.2 ACC 1621 190 0.16 P c.1545g>c ; p.R515S 7 Del exon 1-2 X -2 -2
C 249 USA ND M 1 we 0.2 0 1546 210 0.14 P Del exon 3-21 X Del exon 3-21 X -2 -2
C 96 USA ND F 1 we 0.2 0 1200 176 0.15 P Del exon 1-2 X c.1545G>C ; p.R515S 7 -2 -2
C 33a USA ND F 1 we 0.2 0 888 87 0.10 P c.806C>T ; p.T269M 7 Del exon 1-2 X 1 1
C 33b USA ND F 1 we 0.2 0 808 185 0.23 P c.806C>T ; p.T269M 7 Del exon 1-2 X 1 1
P 60 USA ND F 1 we 0.2 0 810 220 0.27 P Del exon 1-2 X Del exon 1-2 X -2 -2
P 86 USA ND F 1 we 0.2 ACC P c.706C>T ; p.R236X X Del exon 10-21 X -2 -2
P 6 DEK ND F 1  we 0.2 0 1495 350 0.23 P c.2183G>A ; p.G728E 6 c.1545G>C ; p.R515S 7 -1 -1
P 13 USA ND F 1 we 0.2 HCC 832 135 0.16 P Del exon 1-21 X c.1317G>T ; p.K439N 4 -1 -1
P 15 USA ND M 1 we 0.2 ACC 1533 319 0.21 P Del exon 1 X c.1851-1G>A ; IVS15-1G>A S -2 -2
P 19 USA ND M 1 we 0.2 0 1000 96 0.10 P c.1819G>A ; p.G607S 7 Del exon 3-9 X 1 1
P 20 USA ND F 1 we 0.2 HCC 1700 400 0.28 P c.1545G>C ; p.R515S 7 c.2665+1G>C ; IVS22+1G>C S -2 -2
P 41 USA ND F 1 we 0.2 HCC P Del exon 1 X c.2450A>G ; p.Y817C 7 -1 -1
P 44 USA ND F 1 we 0.2 0 1200 100 0.15 P c.2678C>T ; p.P893L 7 c.1545G>C ; p.R515S 7 -2 -2
P 50 USA ND F 1 we 0.2 0 763 150 0.19 P c.1678A>G ; p.M560V 7 c.499G>T ; p.E167X X -1 -1
P 97 USA ND M 1 we 0.2 0 2363 315 0.13 P c.2665+1G>C ; IVS22+1G>C S c.2527C>T ; p.R843X X -2 -2
P 85 USA ND F 1 we 0.2 n.a. 1580 237 0.15 P c.729delCfs ; p.L242Lfs*3 X c.2665+1G>C ; IVS22+1G>C S -2 -2
P 12 USA ND F 1 we 0.2 ACC 1212 277 0.23 T c.344+2+2insT; IVS8+2insT S c.230C>T ; p.S77L 7 -1 -1
P 43 USA ND M 1 we 0.2 n.a. 836 256 0.31 T c.16delA ; p.S6Vfs*90 X c.16delA ; p.S6Vfs*90 X -2 -2
P 24 USA ND M 1 we 0.2 0 939 211 0.22 P c2186delC ; p.A729Efs*3 X c2186delC ; p.A729Efs*3 X -2 -2
P 95 BEL D2Mo F 1 we 0.2 n.a. 708 138 0.19 P c.2422A>C ; p.S808R 3 c.952C>G ; p.Q318E 7 -1 -1
C 42 CAN D3mo M 1 we 0.2 ACC 1446 200 0.14 0 P Dup exon 3-21 X Del exon 16 X -2 -2
C 107 NET Severe M 1 we 0.2 Thin CC ≤ 6 we 4 539 205 0.38 P c.2849A>G ; p.H950R 7 c.2849A>G ; p.H950R 7 -2 -2
C 67 BEL Severe F 1 we 0.2 CerCyst ≤ 6 we 4 830 218 0.29 4.58 0 P Del exon 1-2 X Del exon 4 X -2 -2
C 68 USA Severe M 1 we 0.2 CerCyst ≤ 6 we 3 795 167 0.21 4.87 P Del exon 3-21 X n.a.∫
C 70 BEL Severe F 1 we 0.2 HCC ≤ 6 we 3 1013 112 0.11 30 T c.731dupC; A244Afs*32 X c.959G>A ; p.R320H 7 -1 -2
C 71 GER Severe F 1 we 0.2 HCC ≤ 6 we 3 720 160 0.22 P c.1869T>G ; p.Y632X X c.2281G>C ;  p.G761R 7 -2 -2
C 272 USA Severe M 1 we 0.2 HCC ≤ 6 we 4 1876 499 0.26 3.30 P Del exon 1-2 X Del exon 3-21 X -2 -2
C 38 USA Severe M 1 we 0.2 HCC ≤ 6 we 2 1044 341 0.33 P Del exon 3-25 X c. 382C>T; p. Q128X X -2 -2
C 240 USA Severe F 1 we 0.2 ACC ≤ 6 we 4 594 267 0.45 P c.1545G>C ;  p.R515S 7 c.1545G>C ;  p.R515S 7 -2 -2
C 318 UK Severe M 1 we 0.2 ACC ≤ 6 we 2 1241 190 0.15 P c.1545G>C ; p.R515S 7 c.2316-1G>A ; p.IVS19-1G>A S -2 -2
C 73 GER Severe M 1 we 0.2 0 ≤ 6 we 3 424 40 0.09 3.62 23 83 T c.959G>A ;  p.R320H 7 c.665G>A; p.R222H 7 0 -1
C 74 GER Severe M 1 we 0.2 0 ≤ 6 we 2 830 156 0.19 10 T c.887G>A ;  p.R296H 7 c.845C>T ;  p.T282I 7 0 0
C 75 GER Severe M 6 we 6 0 ≤ 6 we 3 1337 184 0.14 4.81 0 T c.496C>T ;  p.Q166X X c.696+5G>C ; IVS6+5G>C‡ S -2 -2
C 173 POR Severe F 1 we 0.2 HCC ≤ 6 we 3 469 112 0.24 P Del exon 1-2 X Del exon 1-2 X -2 -2
C 121 TAI Severe M 1 we 0.2 HCC ≤ 6 we 5 1287 267 0.21 T c.826G>C ;  p.D276H 7 c.826G>C ;  p.D276H 7 0 0
C 108 USA Severe M 2 mo 2 ACC ≤ 6 we 2 706 210 0.30 4.04 T c.280C>T ; p.R94W 7 c.471+2T>C ; IVS4+2T>C S -1 -1
C 207 USA Severe F 1 we 0.2 0 ≤ 6 we 4 502 127 0.25 P c.127_128delAfs*47 ;  p.D43Wfs*47 X c.2919+1G>C ; IVS24+1G>C S -2 -2
C 312 PUE Severe F 1 we 0.2 ACC ≤ 6 we 2 1944 474 0.24 P c.499G>T ;  p.E167X X c.499G>T ;  p.E167X X -2 -2
C 186 USA Severe F 1 we 0.2 Hydroc ≤ 6 we 4 1559 340 0.22 P Del exon 1-2 X c.2665+1G>C ; IVS22+1G>C S -2 -2
C 316 USA severe F 1 we 0.2 HCC ≤ 6 we 3 2084 510 0.24 2.84 P c.2665+2T>C ; IVS22+2T>C S Del exon 8 X -2 -2
C 327 USA Severe M 1 we 0.2 0 ≤ 6 we 2 1370 395 0.29 P Del exon 1-17 X c.2665+1G>C ; IVS22+1G>C S -2 -2
C 72 SWE Severe M 2 mo 2 0 < 6we 4 342 142 0.42 4.02 0 39 P unknown c.1705G>A ; p.A569T 2 -1 -1
C 329 GER Severe M 1 we 0.2 HCC ≤ 6 we 3 1080 252 0.23 10 P c.911C>T ; p.P304L 6 c.1705G>A ; p.A569T 2 -2 -2
C 225 USA Severe M 1 we 0.2 ACC ≤ 6 we# 3 1400 243 0.17 P c.499G>T ; p.E167X X c.395C>T ; p.S132L 6 -2 -2
P 39 USA Severe F 1 we 0.2 0 1500 300 0.2 P c.1969A>C; S657R 7 c.2405C>T ; p.A802V 5 1 1
P 4 USA Severe M 1 we 0.2 n.a. 491 P c.1381C>T ; p.R461W 7 c.1381C>T ; p.R461W 7 0 0
P 5 USA Severe M 1 we 0.2 0 1385 288 0.21 P c.2919+1G>A ; IVS24+1G>A S c.2250-1G>A ; IVS19-1A>G S -2 -2
P 7 USA Severe F 1 we 0.2 ACC 1797 255 0.15 P Del exon 1-24 X c.2720C>T ; p.P907L 7 -1 -1
P 10 USA Severe F 1 we 0.2 HCC 1811 389 0.21 P c.1545G>C ; p.R515S 7 c.1852G>A ; p.G618R 7 -2 -2
C 11 USA Severe F 1 we 0.2 n.a. 2 P c.2250-1G>A ; IVS19-1A>G S c.2198C>T ; p.A733V 6 -1 -1
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P 14 USA Severe F 1 we 0.2 HCC 1140 440 0.39 P c.1270C>T ; p.R424X X c.1270C>T ; p.R424X X -2 -2
P 21 NWZ Severe F 1 we 0.2 0 1117 257 0.23 P c.495C>T ; p.S132L 6 c.495C>T ; p.S132L 6 -2 -2
P 23 NWZ Severe M n.a. n.a. P c.495C>T ; p.S132L 6 c.2423G>T ; p.S808I 3 -1 -1
P 25 USA Severe F 1 we 0.2 HCC 438 197 0.45 P c.2481_2484delACAA ; p.K827Kfs*7 X c.2416G>C ; p.G806R 7 -1 -1
P 28 USA Severe F 1 we 0.2 0 1264 189 0.15 P c.1444delG ; p.D482Tfs*57 X c.2250-1G>A ; IVS19-1A>G S -2 -2
P 30 USA Severe F 1 we 0.2 0 582 238 0.41 P Del exon 1-4 X Del exon 1-4 X -2 -2
P 34 USA Severe M 1 we 0.2 n.a. P c.2980G>A ; p.G994R 7 c.2584G>A ; p.E862K 7 0 0
P 46 USA Severe M 1 we 0.2 ACC 869 191 0.22 P c.2250-1G>A ; IVS19-1A>G S c.1545G>C ; p.R515S 7 -2 -2
P 48 USA Severe F 1 we 0.2 n.a. P c.800C>T ; p.P267L 6 2415G>A ; p.W805X X -1 -1
P 53 USA Severe F 1 we 0.2 HCC 1626 281 0.17 P c.2458-2A>G ; IVS21-2A>G S Del exon 4-9 X -2 -2
P 54 USA Severe F 1 we 0.2 HCC 1326 178 P c.2021T>A ; p.Y673X X c.2654T>C ; p.L885P 7 -1 -1
P 58 USA Severe M 2 we 0.5 HCC 990 215 0.22 P c.2250-1G>A ; IVS19-1A>G S c.2311G>A ; p.G771R 6 -1 -1
P 62 NWZ Severe F 1 we 0.2 n.a. 1354 271 0.2 P c.1310C>T ; p.T437I 7 c.495C>T ; p.S132L 6 -2 -2
P 82 USA Severe F 1 we 0.2 HCC, SG 0.16 P Del exon 1-25 X c.1000T>C ; p.F334L 5 -1 -1
P 83 USA Severe M 1 we 0.2 ACC 100 P Del exon 1-4 X Del exon 1-4 X -2 -2
P 87 USA Severe F 2 we 0.5 n.a. 900 P c.2665+2T>C ; IVS22+2T>C S c.1869insAT ; p.Y623Mfs*10 X -2 -2
P 98a USA Severe M 1 we 0.4 ACC 1816 P
c.2775insA+c.2776TTCG>CAGA ; 
p.I926Nfs*6 X Del exon 4-15 X -2 -2
P 98b USA Severe F 1 we 0.4 ACC 1537 357 0.23 P
c.2775insA+c.2776TTCG>CAGA ; 
p.I926Nfs*6 X Del exon 4-15 X -2 -2
P 99 USA Severe M 1 we 0.4 n.a. 1914 211 0.11 P c.2665+1G>C ; IVS22+1G>C S unknown n.a. -1 -1
P 2 USA Severe M 1 mo 1 0 610 87 0.14 T c.2T>C; p.M1T 5 c.2T>C; p.M1T 5 0 -2
P 17 GRE Severe M 1 we 0.2 HCC 573 82 0.14 T c13_16delGTAA ; p.S5Vfs*27 X c.350C>T ; p.S117L 6 -1 -1
P 22 USA Severe F 1 we 0.2 n.a. 610 134 0.22 T c.2T>C; p.M1T 5 c.2T>C; p.M1T 5 0 -2
P 47 USA Severe F 6 we 1.5 HCC, DW 714 103 0.14 T c.674G>C ; p.Y225C* 7 c.635T>C ; p.V212A 7 0 0
P 56 USA Severe F 1 we 0.2 n.a. T c.959G>A ; p.R320H 7 c.959G>A ; p.R320H 7 0 -2
P 59 USA Severe M 1 we 0.2 BA T c.1040_1041delTG ; p.V347Dfs*2 X c.230C>T ; p.S77L 7 -1 -1
C 204 USA Severe M 1 we 0.2 n.a. 3 1067 193 0.18 P c.1869T>G ; p.Y623X X Del exon 1 X -2 -2
C 35 USA Severe F 1 we 0.2 HY 969 160 0.16 P c.1166C>T ; p.A389V 7 c.1545G>C ; p.R515S 7 1 1
C 330 GER Att poor M 1 we 0.2 0 5 1 925 172 0.19 P c.1642C>G ; p.L548V* 7 Del exon 1-25 X 1 1
C 76 ITA Att Poor M 1 we 0.2 0 11 0 867 104 0.12 2.83 P c.1097A>G ;  p.Q366R 7 c.1097A>G ;  p.Q366R 7 4 4
C 245a USA Att Poor M 1.5 mo 1.5 0 11 0 552 103 2.30 P c.2405C>T ; p.A802V 5 c.2665+1G>C ; IVS22+1G>C S 1 1
C 310 USA Att Poor M 1 we 0.2 HCC 12 1 820 140 0.17 3.10 P c.2203-2A>G ; IVS18-2A>G S c.547delGfs*38 ; p.V183Gfs*38 X -1 1
C 165 USA Att Poor F 1 we 0.2 0 13 2 1433 156 0.11 P c.2405C>T ; p.A802V 7 c.1545 G>C ; p.R515S 7 1 1
C 45a USA Att Poor F 1 we 0.2 0 14 2 637 136 0.21 2.52 P c.1580+2T>G ; p.IVS12+2T>G S c.1166C>T ;  p.A389V 7 1 1
C 78 NET Att Intermediate M 1 we 0.2 0 21 1 675 85 0.13 1.90 17 53 T c.959G>A ;  p.R320H 5 c.317T>C ;  p.I106T 7 0 1
C 77 NET Att Intermediate F 1 we 0.2 0 23 0 1068 230 0.22 0.92 31 39 T c.317T>C ;  p.I106T 7 c.515T>C ;  p.L172P 7 0 2
C 148 USA Att Intermediate M 3 mo 3 0 24 3 606 103 0.17 P c.1166C>T p. A389V† 7 c.1545G>C p.R515S† 7 1 1
C 248 USA Att Intermediate F 6 we 6 0 25 1 859 139 0.16 P c.1142T>C ;  p.I381T 7 c.1382G>A ; p.R461Q 7 4 4
C 61a USA Att Intermediate M 1 we 0.2 0 27 3 1001 110 0.11 P c.847G>C ; p.A283P 5 c.1382G>A ; p.R461Q 6 1 1
C 61b USA Att Intermediate M 3 mo 3 0 30 2 509 73 0.14 P c.847G>C ; p.A283P 5 c.1382G>A ;  p.R461Q 6 1 1
C 45b USA Att Intermediate F 3 mo 3 0 30 3 567 0.68 P c.1580+2T>G ; p.IVS12+2T>G S c.1166C>T ;  p.A389V 7 1 1
C 79 GER Att Intermediate M 1 we 0.2 0 30 0 1120 200 0.18 1.80 30 P c.1382G>A ;  p.R461Q 6 c.1929-2A>G ; IVS17-2A>G S 1 1
C 159 NET Att Intermediate F 2 mo 2 0 30 0 826 85 0.10 T c.317T>C ;  p.I106T 7 c.665G>C ;  p.R222H 7 0 2
C 234 YEM Att Intermediate M 4 mo 4 0 30 0 850 51 0.06 P c.482A>G ;  p.Y161C 7 c.1041A>C ;  p.R347S 7 0 0
C 32a CAN Att Intermediate F 6 we 1.5 0 37 0 578 89 0.15 P c.605C>T  ; p.A202V 7 c.2665+1G>C ; IVS22+1G>C S 1 1
C 245b USA Att Intermediate M 1 we 0.2 0 48 0 693 85 0.12 1.84 P c.2405C>T ; p.A802V 5 c.2665+1G>C ; IVS22+1G>C S 1 1
C 40 NET Att Good M 5 mo 5 0 50 0 470 53 0.11 T c.317T>C ;  p.I106T 7 c.959G>A ;  p.R320H 7 0 1
C 81a USA Att Good M 1 we 0.2 0 51 0 920 63 0.07 24 P c.1166C>T ;  p.A389V 7 c.1166C>T ;  p.A389V 7 4 4
C 81b USA Att Good F 1 we 0.2 0 52 0 915 10 P c.1166C>T ;  p.A389V 7 c.1166C>T ;  p.A389V 7 4 4
C 80 GER Att Good F 12 mo 12 0 55 0 890 100 0.11 1.51 0 P c.2999delG fs*30 ; p.C1000Lfs*30 X¶ c.1270C>T ;  p.R424X X -1 1
C 322 DK Att Good M 11 mo 11 0 56 0 829 66 0.08 P c.466G>T ; p.G516R 5 c.2183G>A ; p.G728E 6 0 0
C 18 USA Att Good M 1 we 0.2 0 58 0 1196 P Del exon 3-21 X c.2032-2034delCAG ; p.A678del 7 1 1
C 32b CAN Att Good M 1 we 0.2 0 58 0 720 48 0.07 P c.605C>T  ; p.A202V 7 c.2665+1G>C ; IVS22+1G>C S 1 1
C 298 BEL Att Good M 1 we 0.2 0 60 0 584 88.7 0.15 0.24 P c.1889G>C ;  p.R630P 7 c.1642C>G ;  p.L548V 7 4 4
C 16 USA Att Good M 3 yr 36 0 60 0 697 T c.959G>A ;  p.R320H 7 c.664C>T ; p.R222C 7 0 -1
C 222 USA Att Good F 1 we 0.2 0 67 0 930 154 0.17 1.25 P c.2315+2T>G ;  IVS19+2T>G S c.2405C>A ;  p.A802E 5 1 1
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C 196 USA Att Good M 4 mo 4 0 70 0 800 P c.806C>T ; p.T269M 7 c.806C>T ; p.T269M 7 4 4
C 218 USA Att Good M 10 mo 10 0 70 0 645 74 P c.2714T>C ; p.V905G 2 c.2183G>A ; p.G728E 6 0 0
C 92 USA Att Good F 2 yr 4 mo 28 0 70 0 930 62 P c.1955G>A ;  p.G652E 7 c.1118G>A ; p.R373Q* 6 0 0
C 51 AUS Att Good M 1 we 0.2 0 75 0 713 46 0.06 P c.872G>A ; p.C291Y 2 c.872G>A ; p.C291Y 2 4 4
P 315 CAN Att Good M 3 yr 36 0 82 0 932 41.4 0.04 P c.605C>T  ; p.A202V 7 c.605C>T ;  p.A202V 7 4 4
P 52 USA Attenuated NOS M 7 we 1.75 0 1590 122 0.077 P Del exon 3-21 X c.2405C>T ; p.A802V 5 1 1
P 294 NOR Attenuated NOS F 2 we 0.5 0 503 91 0.18 P c.1145G>A ; p.C382Y 7 c.2405C>T ; p.A802V 5 1 1
P 31 NWZ Attenuated NOS F 3 mo 3 0 342 43 0.12 P c.495C>T ; p.S132L 6 c.245T>C ; p.L82S 3 1 1
P 55 USA Attenuated NOS M 7 mo 7 n.a. 1011 50 0.05 P c.1078G>C ; p.V360L 2 c.2838G>A ; IVS23+5G>A S -1 -1
P 90 USA Attenuated NOS M 1 we 0.2 HCC 758 67 0.08 P c.2798T>C ; p.I933T 4 c.811G>A ; p.G271R 7 0 0
P
9 USA Attenuated NOS M 1 mo 1 n.a. P c.1819G>A ; G607S 7 c1580delGinsCAA ; p.S527Tfs*13 X 1 1
P 296 USA Attenuated NOS M 1 we 0.2 HCC 1284 P c.1738C>G ; p.H580D 7 c.1844C>T ; p.P615L 7 0 0
P 325 NWZ Attenuated NOS F 6 we 1.5 0 590 55 0.09 P Del exon 16-25 X c.605C>T ; p.A202V 7 1 1
P 278 USA Attenuated NOS M 1 we 0.2 0 870 175 0.21 P c.1166C>T ; p.A389V 7 Del exon 2 X 1 1
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cDNA Protein Western Blot Activity Effect Subject Other allele Clinical severity
c.245T>C p.L82S Stable 34 % ± 8.9 Very mild 31 p.S132L severe Attenuated
c.495C>T p.S132L Unstable BDL Severe 225 p.E167X severe Severe
21 Homozygous Severe
23 p.S808I likely severe Severe
62 p.T437I severe Severe
31 p.L82S very mild Attenuated
c.605C>T p.A202V Less Stable 18.2 % ± 3.43 Very mild 325 Del Ex 16-25 Attenuated
32a IVS22+1G>C severe Attenuated intermediate
32b IVS22+1G>C severe Attenuated mild
315 Homozygous Attenuated mild
c.806C>T p.T269M Unstable  1.3 % ± 0.21 Mild 196 Homozygous Attenuated mild
33a Deletion exon 1-2 severe Neonatal death, no poor sign
33b Deletion exon 1-2 severe Neonatal death, no poor sign
c.847G>C p.A283P Unstable 0.5%± 0.043 Intermediate 61a p.R461Q Attenuated intermediate
61b p.R461Q Attenuated intermediate
c.873C>G p.C291Y Unstable  1.1 % ± 0.33 Mild 51 Homozygous Attenuated mild
c.911C>T p.P304L Unstable BDL Severe 329 p.A569T severe Severe
c.1097A>G p.Q366R Stable  1.1 % ± 0.19 Mild 76 Homozygous Attenuated poor
c.1142C>T p.I381T Stable 32.3 % ± 8.69 Very mild 248 p.R461Q Intermediate Attenuated intermediate
c.1145G>A p.C382Y Stable BDL Severe 294 p.A802V Very mild Attenuated
c.1166C>T p.A389V Stable 11.9 % ± 2.53 Very mild 35 p.R515S severe Severe
45a IVS12+2T>G severe Attenuated poor
148 p.R515S severe Attenuated intermediate
45b IVS12+2T>G severe Attenuated intermediate
81a Homozygous Attenuated mild
81b Homozygous Attenuated mild
278 Deletion exon 2 Attenuated
c.1310C>T p.T437I Unstable BDL Severe 62 p.S132L severe Severe
c.1382G>A p.R461Q Less Stable 0.65% ± 0.27 Intermediate 248 p.I381T very mild Attenuated intermediate
61a p.A283P intermediate Attenuated intermediate
61b p.A283P intermediate Attenuated intermediate
79 IVS17-2A>G severe Attenuated intermediate
c.1545G>C p.R515S Unstable BDL Severe 240 Homozygous Severe
318 IVS19-1G>A severe Severe
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10 p.G618R severe Severe
46 IVS19-1G>A severe Severe
168 Deletion exon 1-2 Neonatal death, ACC
6 p.G728E unknown Neonatal death, CSF gly 350
20 IVS22+1G>C severe Neonatal death, HCC CSF gly 400
44 p.P893L severe Neonatal death, no indicator
96 Deletion exon 1-2 severe Neonatal death, no indicator
35 p.A389V very mild Severe
148 p.A389V very mild Attenuated intermediate
165 p.A802V very mild Attenuated poor
c.1642C>G p.L548V Stable 22.5% ± 3.08 Very mild 330 Deletion exon 1-25 Attenuated poor
298 p.R630P mild Attenuated mild
c.1705G>A p.A569T Unstable BDL Severe 329 p.P304L severe Severe
72 Unknown Severe
c.1819G>A p.G607S Unstable 2.04% ± 0.57 Mild 9 p.S527Tfs*13 severe Attenuated
19 Deletion exon 3-9 severe Neonatal death, no indicator
c.1852G>A p.G618R Stable BDL Severe 10 p.R515S severe Severe
c.1889G>C p.R630P Less Stable 10% ± 1.0 Mild 298 p.L548V very mild Attenuated mild
c.1969A>C p.S657R Stable BDL Severe 39 p.A802V very mild Severe
c.2032delCAG p.A678del Less Stable 0.30% ± 0.12 Intermediate 18 Deletion exon 3-21 Attenuated mild
c.2281G>C p.G761R Stable BDL Severe 71 p.Y632X severe Severe
c.2405C>T p.A802V Less Stable 25.8 % ± 4.4 Very mild 52 Deletion ex 3-21 Attenuated
245a IVS22+1G>C severe Attenuated poor
245b IVS22+1G>C severe Attenuated intermediate
165 p.R515S severe Attenuated poor
294 p.C382Y severe Attenuated
39 p.S657R severe Severe
c.2405C>A p.A802E Stable 8.8 % ± 0.73 Mild 222 IVS19+2T>G severe Attenuated mild
c.2422A>C p.S808R Stable BDL Severe 69 p.Q180X severe Neonatal death, ACC
95 p.Q318E unknown Infantile death, no indicator
c.2498C>T p.A833V Stable BDL Severe 27 Deletion exon 1-2 Neonatal death
c.2678C>T p.P893L Stable BDL Severe 44 p.R515S severe Neonatal death, no indicator
x.2849A>G p.H950R Stable BDL Severe 107 Homozygous Severe
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ACC, agenesis of the corpus callosum
BA, brain atrophy
DW, Dandy Walker
HCC, hypoplastic corpus callosum
HY, hydrocephalus
NA, not available
SC, simplified gyral pattern
a and b are sibling pairs
* de novo mutation
# can roll from back to prone
‡ proven to affect splicing
¶ near end of protein, results in residual activity
† phase not known
AED: number of antiepileptic drugs
Study: C= primary study with consent and complete data; 
Study: P = secondary exempt chart review study with limited data available
Gly = glycine
Enzyme activities are listed as % of normal control
Gly Index = glycine index, molar difference of glycine intake and benzoate needed to normalize plasma glycine 
For AMT: Pan troglodytes, Bos taurus, Danio rerio, Saccharoyces cerevisiae, and Caenorabdhitis elegans
∫ only maternal sample available
Conservation: X = not a missense mutation, a number = number of species in which the mutated amino acid is 
conserved from the 7 species listed in the methods (including human)
For GLDC: Mus musculus, Caenorabdhitis elegans, Drosophila, melanogaster, Saccharomyces cerevisiae, Eschiria 
coli and Arabidopsis thaliana
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